Showing results (421-430 of 464) with videos related to

Sort By:
Pageof 47
Iscience|May 28, 2026
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancerMasaki Ishida, Tadaaki Yamada, Yasuhiro Goto, et al.
Thoracic Cancer|July 17, 2019
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancerHirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, et al.
Translational Lung Cancer Research|May 17, 2023
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targetsMidori Shimada, Hirokazu Taniguchi, Hiroyuki Yamaguchi, et al.
Thoracic Cancer|April 26, 2023
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practiceMinehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, et al.
Translational Lung Cancer Research|November 7, 2024
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)Shinnosuke Takemoto, Minoru Fukuda, Ryosuke Ogata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2022
Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLCEvelyn M Nguyen, Hirokazu Taniguchi, Joseph M Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung CancerNaoko Okura, Naoya Nishioka, Tadaaki Yamada, et al.
Oncogene|July 2, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancerYifeng Liu, Shigeki Nanjo, Yuya Murase, et al.
Lung Cancer (Amsterdam, Netherlands)|January 31, 2025
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patientsTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Anticancer Research|October 28, 2025
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 ExpressionAosa Sasada, Hayato Kawachi, Tadaaki Yamada, et al.
Pageof 47